منابع مشابه
Combination biologic therapy.
Biologic therapies refer to genetically engineered treatments such as monoclonal antibodies and receptor-immunoglobulin fusion proteins. Following many disappointments, the introduction of anti-tumor necrosis factor (anti-TNF alpha) therapies into the clinic has clearly demonstrated the exciting potential of biologic agents. Many of these have been designed to modulate a specific aspect of the ...
متن کاملBiologic therapy-induced pemphigus*
An Bras Dermatol. 2017;92(4):584-95. Dear editor, Pemphigus is an autoimmune bullous disease that can affect the skin and mucous membranes, mediated by autoantibodies against desmosomal desmogleins, the main adhesion structures Marina Zoega Hayashida1 Jhonatan Rafael Siqueira Pinheiro1 Milvia Maria Simões e Silva Enokihara2 Mônica Ribeiro de Azevedo Vasconcellos1 t Biologic therapy-induced pemp...
متن کاملBiologic therapy of psoriatic arthritis.
Psoriatic arthritis is now recognized as a potentially serious and disabling disease. Traditional therapies have not been very effective in controlling signs and symptoms or preventing progression of damage. Based on the pathogenesis of the disease new therapies have been introduced, particularly anti-TNF agents and anti-T cell agents. Several of those have shown excellent responses in clinical...
متن کاملBiologic therapy in lupus nephritis.
This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.
متن کاملRelationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
The prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established and is of particular interest given the opportunities for targeted therapies using FLT3 inhibitors. We studied 203 patients with PML-RARA-positive APL; 43% of the patients had an FLT3 mutation (65 internal tandem duplications [ITDs], 19 D835/I836, 4 ITD+D835/I836). Both mutations were a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2004
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6601432